Dexpramipexole Renal PK Study
NCT01424176 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2014-11-25
Summary
This is a multicenter, open-label, single-dose, PK and safety study in subjects with various stages of renal impairment.
Conditions
- Amyotrophic Lateral Sclerosis
- Renal Insufficiency
Interventions
- DRUG
-
Dexpramipexole (dose 1)
- DRUG
-
Dexpramipexole (dose 2)
Sponsors & Collaborators
-
Knopp Biosciences
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-07-31
- Primary Completion
- 2012-01-31
- Completion
- 2012-01-31
Countries
- United States
Study Locations
More Related Trials
-
A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN
NCT04973657 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose,First-in-human of KLA478
NCT07240675 ·Status: RECRUITING ·Phase: PHASE1
-
Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
NCT00596115 ·Status: TEMPORARILY_NOT_AVAILABLE
-
Dimethyl Fumarate in Adrenomyeloneuropathy
NCT06513533 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.
NCT03196375 ·Status: TERMINATED ·Phase: PHASE2
-
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01486849 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
NCT02271217 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
NCT05808764 ·Status: RECRUITING ·Phase: PHASE2
-
Phase 1 ALKS 1140 in Healthy Adults
NCT05019105 ·Status: TERMINATED ·Phase: PHASE1
-
Trial of Ropinirole in Motor Recovery After Stroke
NCT00221390 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
NCT02422940 ·Status: TERMINATED ·Phase: PHASE3
-
Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS
NCT04987671 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
NCT05006352 ·Status: COMPLETED ·Phase: PHASE1
-
Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
NCT01645787 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis
NCT00140218 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
4-Aminopyridine in Episodic Ataxia Type 2
NCT01543750 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
NCT03757351 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
NCT01468350 ·Status: COMPLETED ·Phase: PHASE1
-
R(+)PPX High Dose Treatment of ALS
NCT00600873 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia
NCT01898884 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS
NCT06249867 ·Status: RECRUITING ·Phase: PHASE2
-
Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)
NCT00931944 ·Status: COMPLETED ·Phase: PHASE2
-
Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome
NCT00152997 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT01281631 ·Status: COMPLETED ·Phase: PHASE2
-
DIalysis Symptom COntrol-Restless Legs Syndrome Trial
NCT03806530 ·Status: COMPLETED ·Phase: PHASE3